Abbott Laboratories (VIE:ABT)
98.63
+0.39 (0.40%)
At close: Feb 27, 2026
Abbott Laboratories Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8,522 | 7,616 | 6,896 | 9,882 | 9,799 |
Short-Term Investments | 417 | 351 | 383 | 288 | 450 |
Trading Asset Securities | - | 1 | - | - | - |
Cash & Short-Term Investments | 8,939 | 7,968 | 7,279 | 10,170 | 10,249 |
Cash Growth | 12.19% | 9.47% | -28.43% | -0.77% | 43.38% |
Receivables | 7,929 | 6,925 | 6,565 | 6,218 | 6,487 |
Inventory | 6,488 | 6,194 | 6,570 | 6,173 | 5,157 |
Prepaid Expenses | 2,532 | 2,179 | 2,087 | 2,251 | 2,054 |
Other Current Assets | 108 | 390 | 169 | 412 | 292 |
Total Current Assets | 25,996 | 23,656 | 22,670 | 25,224 | 24,239 |
Property, Plant & Equipment | 12,942 | 11,733 | 11,276 | 10,278 | 10,112 |
Long-Term Investments | 595 | 573 | 485 | 468 | 512 |
Goodwill | 24,035 | 23,108 | 23,679 | 22,799 | 23,231 |
Other Intangible Assets | 5,526 | 6,647 | 8,815 | 10,454 | 12,739 |
Long-Term Deferred Tax Assets | - | - | 5,975 | - | - |
Other Long-Term Assets | 17,619 | 15,697 | 314 | 5,215 | 4,363 |
Total Assets | 86,713 | 81,414 | 73,214 | 74,438 | 75,196 |
Accounts Payable | 4,240 | 4,195 | 4,295 | 4,607 | 4,408 |
Accrued Expenses | 7,173 | 6,200 | 6,543 | 6,925 | 6,464 |
Current Portion of Long-Term Debt | 3,033 | 1,500 | 1,080 | 2,271 | 754 |
Current Portion of Leases | 276 | 254 | 245 | 230 | 245 |
Current Income Taxes Payable | 569 | 594 | 492 | 343 | 306 |
Other Current Liabilities | 1,205 | 1,414 | 1,186 | 1,113 | 928 |
Total Current Liabilities | 16,496 | 14,157 | 13,841 | 15,489 | 13,105 |
Long-Term Debt | 9,896 | 12,676 | 13,694 | 14,522 | 17,296 |
Long-Term Leases | 931 | 896 | 949 | 943 | 956 |
Pension & Post-Retirement Benefits | 2,125 | 1,880 | 1,964 | 1,784 | 2,738 |
Long-Term Deferred Tax Liabilities | 559 | 512 | 568 | 991 | 1,392 |
Other Long-Term Liabilities | 3,935 | 3,392 | 3,371 | 3,804 | 3,685 |
Total Liabilities | 33,942 | 33,513 | 34,387 | 37,533 | 39,172 |
Common Stock | 25,527 | 25,153 | 24,869 | 24,709 | 24,470 |
Retained Earnings | 49,781 | 47,261 | 37,554 | 35,257 | 31,528 |
Treasury Stock | -17,177 | -16,844 | -15,981 | -15,229 | -11,822 |
Comprehensive Income & Other | -6,001 | -7,906 | -7,839 | -8,051 | -8,374 |
Total Common Equity | 52,130 | 47,664 | 38,603 | 36,686 | 35,802 |
Minority Interest | 641 | 237 | 224 | 219 | 222 |
Shareholders' Equity | 52,771 | 47,901 | 38,827 | 36,905 | 36,024 |
Total Liabilities & Equity | 86,713 | 81,414 | 73,214 | 74,438 | 75,196 |
Total Debt | 14,136 | 15,326 | 15,968 | 17,966 | 19,251 |
Net Cash (Debt) | -5,197 | -7,358 | -8,689 | -7,796 | -9,002 |
Net Cash Per Share | -2.97 | -4.21 | -4.97 | -4.42 | -5.03 |
Filing Date Shares Outstanding | 1,738 | 1,734 | 1,735 | 1,738 | 1,763 |
Total Common Shares Outstanding | 1,737 | 1,732 | 1,734 | 1,738 | 1,764 |
Working Capital | 9,500 | 9,499 | 8,829 | 9,735 | 11,134 |
Book Value Per Share | 30.02 | 27.52 | 22.26 | 21.11 | 20.29 |
Tangible Book Value | 22,569 | 17,909 | 6,109 | 3,433 | -168 |
Tangible Book Value Per Share | 13.00 | 10.34 | 3.52 | 1.98 | -0.10 |
Land | 541 | 528 | 529 | 511 | 525 |
Buildings | 4,543 | 4,207 | 4,161 | 4,053 | 4,007 |
Machinery | 17,571 | 15,517 | 15,179 | 14,164 | 13,528 |
Construction In Progress | 2,567 | 2,488 | 2,064 | 1,484 | 1,304 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.